Current Advances

Isis Pharmaceuticals Discusses its Pipeline in Four Conference Calls

Isis has conducted a series of four conference calls, each call focused on a specific therapeutic franchise in Isis’ development pipeline. Transcripts are available for download for each of the four calls as well as access to the archived webcasts below.

Isis' Neurodegenerative Franchise

>To access the archived webcast and transcript of the neurodegenerative call

Isis is pursuing the discovery and development of antisense drugs for neurodegenerative diseases in which there is a large unmet need for new treatment options. Isis’ initial goal is to develop antisense drugs to treat severe diseases with identified genetic causes. Isis has initiated several programs to develop drugs to treat severe neurodegenerative disease and funded three of these programs in part through grants. The most advanced program in Isis’ neurodegenerative franchise is its SOD1 drug to treat amyotrophic lateral sclerosis, or ALS, also known as Lou Gehrig’s disease. Isis recently added a drug designed to treat spinal muscular atrophy into its development pipeline and is developing novel treatments for other severe neurodegenerative diseases.

Isis' Cancer Franchise

To access the archived webcast and transcript of the call

Cancer accounts for nearly one-quarter of deaths in the United States. The American Cancer Society predicts that one in two American men and one in three American women will develop cancer. Isis is pursuing the discovery and development of antisense drugs to treat multiple types of cancer in its own programs and through its partnerships with OncoGenex Technologies Inc. and Eli Lilly and Company. Isis and its partners have presented clinical data on multiple anti-cancer antisense drugs demonstrating that antisense drugs reduce disease targets in humans with cancer and provide therapeutic benefit at doses that are well tolerated. In addition to the drugs in its development pipeline, Isis’ cancer franchise includes a variety of early stage programs that could offer new approaches to treating cancer.

Isis' Metabolic Franchise

To access the archived webcast and transcript of the call

Isis is pursuing the discovery and development of antisense drugs to treat metabolic diseases, such as diabetes and obesity. According to the Centers for Disease Control and Prevention, diabetes affects more than 20 million people in the U.S. Isis has four drugs in its pipeline to treat type 2 diabetes, each of which acts upon targets in the liver, fat tissue or the kidney through distinct mechanisms to improve insulin sensitivity, reduce glucose production, or affect other metabolic aspects of metabolic disease. Isis is developing other drugs aimed at other types of metabolic diseases, including obesity.

Isis' Cardiovascular Franchise

To access the archived webcast and transcript of the call

Isis is pursuing the discovery and development of antisense drugs to treat cardiovascular disease, the leading cause of death in the United States. Mipomersen, the most advanced drug in Isis' cardiovascular pipeline, is in development to treat patients with high cholesterol, who are at high cardiovascular risk. Isis is developing other drugs that could aid in lipid management, produce safer, more effective antithrombotic activity and address inflammatory processes involved in cardiovascular and other diseases.